Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$3.08M$3.08M+473.9% vs Q2 2024 Net Income-$36.95M-$36.95MN/M vs Q2 2024 EPS Diluted-$0.28-$0.28N/M vs Q2 2024 Operating Income-$38,653,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,546,000N/M Margins · derivedOperating margin-1256.6%+5108.0 pt vs Q2 2024
Net margin-1201.3%+4705.6 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end